ARTICLE | Clinical News
SBC-102 regulatory update
November 15, 2010 8:00 AM UTC
The European Commission granted Orphan Drug designation for Synageva's SBC-102 to treat lysosomal acid lipase (LAL) deficiency (Wolman disease). The recombinant human LAL enzyme replacement therapy (...